VivoSeq
Infectious Disease

Impetigo

10

Pipeline Programs↗

0

Active Trials↗

9

Companies Involved↗

Impetigo is an early-stage landscape with 10 programs across 9 companies. The most active players are NovaBay Pharmaceuticals, Inc., Lytix Biopharma AS, Vyne Therapeutics Inc.. 2 therapies are approved with 4 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

36/100

Pipeline Velocity

0/100

Mech. Concentration

67/100

Completion Rate

93/100

Attrition Rate

6/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

N

NovaBay Pharmaceuticals, Inc.

1 program

Phase 2L

Lytix Biopharma AS

1 program

Phase 2V

Vyne Therapeutics Inc.

1 program

Phase 2U

UNION therapeutics

1 program

Phase 2GSK logo

GSK

2 programs

Phase 3Pfizer logo

Pfizer

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Trial Status

16

clinical trials

Completed13 · 81%
Unknown status2 · 13%
Terminated1 · 6%

Clinical Trials

Trial Activity

16 trials

Treatment Of Impetigo With Topical SB-275833 Ointment, 1% Versus Topical Placebo Ointment
Completed·GSK logoGSK·Phase 3·NCT00133848·210 enrolled
Study to Evaluate the Safety and Efficacy of Topical Minocycline FXFM244 in Impetigo Patients
Completed·VVyne Therapeutics Inc.·Phase 2·NCT01171326·32 enrolled
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
Completed·GSK logoGSK·Phase 3·NCT00852540·410 enrolled
Study Evaluating the Safety, Tolerability, PK, and Activity of Topical ATx201 Gel in Outpatients With Impetigo
Completed·UUNION therapeutics·Phase 2·NCT03429595·210 enrolled
Vehicle Controlled Efficacy and Safety Study of Two Dose Regimens of CD07223 1.5% Topical Gel in Impetigo
Completed·NNovaBay Pharmaceuticals, Inc.·Phase 2/3·NCT01670032·328 enrolled
Safety and Efficacy of Topical NVC-422 Gel in Impetigo
Completed·NNovaBay Pharmaceuticals, Inc.·Phase 2·NCT01367314·129 enrolled
Topical SB-275833 Ointment, 1% For The Treatment Of Impetigo
Completed·GSK logoGSK·Phase 3·NCT00133874·520 enrolled
Efficacy, Safety, and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic Lesions (SITL)
Completed·LEO Pharma logoLEO Pharma·Phase 2·NCT00626795·773 enrolled
The Pharmacokinetics of 2% TD1414 Cream in Adults With Secondarily Infected Traumatic Lesions (SITL) or Impetigo
Completed·LEO Pharma logoLEO Pharma·Phase 2·NCT00758862·20 enrolled
Safety and Efficacy of Mupirocin Gel in Children With Impetigo
Completed·RReig Jofre Group·Phase 3·NCT04287777·467 enrolled
Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo
Completed·—·Phase 3·NCT01397461·465 enrolled
A Phase II Study to Evaluate the Efficacy and Safety of Two Doses of LTX-109 in Impetigo
Completed·LLytix Biopharma AS·Phase 2·NCT01803035·210 enrolled
Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo
Completed·—·Phase 3·NCT02090764·412 enrolled
Fucidin® Cream in the Treatment of Impetigo
Terminated·LEO Pharma logoLEO Pharma·Phase 4·NCT00986856·58 enrolled
Citriodiol® and Impetigo
Unknown status·RRoyal North Shore Hospital·Phase 2/3·NCT01611909·30 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)